1 |
Lai, A. C. and Crews, C. M. (2017) Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101-114.
DOI
|
2 |
Singh, B., Carpenter, G. and Coffey, R. J. (2016) EGF receptor ligands: recent advances. F1000Res. 5, 2270.
DOI
|
3 |
Tinivella, A. and Rastelli, G. (2018) Investigating the selectivity of allosteric inhibitors for mutant T790M EGFR over wild type using molecular dynamics and binding free energy calculations. ACS Omega 3, 16556-16562.
DOI
|
4 |
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J. and Yarden, Y. (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 16, 5276-5287.
DOI
|
5 |
Vyse, S. and Huang, P. H. (2019) Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct. Target. Ther. 4, 5.
DOI
|
6 |
Wang, Y., Guo, Z., Li, Y. and Zhou, Q. (2016) Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma. Open Med. (Wars.) 11, 68-77.
DOI
|
7 |
Wee, P. and Wang, Z. (2017) Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel) 9, 52.
DOI
|
8 |
Bhullar, K. S., Lagaron, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P. and Rupasinghe, H. P. V. (2018) Kinase-targeted cancer therapies: progress, challenges and future directions. Mol. Cancer 17, 48.
DOI
|
9 |
Lategahn, J., Keul, M., Klovekorn, P., Tumbrink, H. L., Niggenaber, J., Muller, M. P., Hodson, L., Flasshoff, M., Hardick, J., Grabe, T., Engel, J., Schultz-Fademrecht, C., Baumann, M., Ketzer, J., Muhlenberg, T., Hiller, W., Gunther, G., Unger, A., Muller, H., Heimsoeth, A., Golz, C., Blank-Landeshammer, B., Kollipara, L., Zahedi, R. P., Strohmann, C., Hengstler, J. G., van Otterlo, W. A. L., Bauer. S. and Rauh, D. (2019) Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. Chem. Sci. 10, 10789-10801.
DOI
|
10 |
Du, Z. and Lovly, C. M. (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol. Cancer 17, 58.
DOI
|
11 |
Carpenter, C. D., Ingraham, H. A., Cochet, C., Walton, G. M., Lazar, C. S., Sowadski, J. M., Rosenfeld, M. G. and Gill, G. N. (1991) Structural analysis of the transmembrane domain of the epidermal growth factor receptor. J. Biol. Chem. 266, 5750-5755.
DOI
|
12 |
Midha, A., Dearden, S. and McCormack, R. (2015) EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am. J. Cancer Res. 5, 2892-2911.
|
13 |
Li, A. R., Chitale, D., Riely, G. J., Pao, W., Miller, V. A., Zakowski, M. F., Rusch, V., Kris, M. G. and Ladanyi, M. (2008) EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J. Mol. Diagn. 10, 242-248.
DOI
|
14 |
Lin, Y., Wang, X. and Jin, H. (2014) EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am. J. Cancer Res. 4, 411-435.
|
15 |
Maity, S., Pai, K. S. R. and Nayak, Y. (2020) Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance. Pharmacol. Rep. 72, 799-813.
DOI
|
16 |
Olsen, J. V., Blagoev, B., Gnad, F., Macek, B., Kumar, C., Mortensen, P. and Mann, M. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-648.
DOI
|
17 |
Purba, E. R., Saita, E. I. and Maruyama, I. N. (2017) Activation of the EGF receptor by ligand binding and oncogenic mutations: the "rotation model". Cells 6, 13.
DOI
|
18 |
Zarogoulidis, P., Lampaki, S., Chinelis, P., Lazaridis, G., Baka, S. and Rapti, A. (2016) Tyrosine kinase inhibitors for non-small cell lung cancer and eye metastasis: disease relapse or a new entity? Med. Hypothesis Discov. Innov. Ophthalmol. 5, 132-135.
|
19 |
De Clercq, D. J. H., Heppner, D. E., To, C., Jang, J., Park, E., Yun, C. H., Mushajiang, M., Shin, B. H., Gero, T. W., Scott, D. A., Janne, P. A., Eck, M. J. and Gray, N. S. (2019) Discovery and optimization of dibenzodiazepinones as allosteric mutant-selective EGFR inhibitors. ACS Med. Chem. Lett. 10, 1549-1553.
DOI
|
20 |
Ferguson, K. M., Berger, M. B., Mendrola, J. M., Cho, H. S., Leahy, D. J. and Lemmon, M. A. (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 11, 507-517.
DOI
|
21 |
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M. and Boyle, P. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18, 581-592.
DOI
|
22 |
Finlay, M. R., Anderton, M., Ashton, S., Ballard, P., Bethel, P. A., Box, M. R., Bradbury, R. H., Brown, S. J., Butterworth, S., Campbell, A., Chorley, C., Colclough, N., Cross, D. A., Currie, G. S., Grist, M., Hassall, L., Hill, G. B., James, D., James, M., Kemmitt, P., Klinowska, T., Lamont, G., Lamont, S. G., Martin, N., McFarland, H. L., Mellor, M. J., Orme, J. P., Perkins, D., Perkins, P., Richmond, G., Smith, P., Ward, R. A., Waring, M. J., Whittaker, D., Wells, S. and Wrigley, G. L. (2014) Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J. Med. Chem. 57, 8249-8267.
DOI
|
23 |
Tokudome, N., Koh, Y., Akamatsu, H., Fujimoto, D., Okamoto, I., Nakagawa, K., Hida, T., Imamura, F., Morita, S. and Yamamoto, N. (2020) Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. BMC Cancer 20, 103.
DOI
|
24 |
Yun, C. H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M. and Eck, M. J. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11, 217-227.
DOI
|
25 |
Abdallah, S. M. and Hirsh, V. (2018) Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer. Curr. Oncol. 25, S9-S17.
DOI
|
26 |
Akazawa, Y., Saito, Y., Yoshikawa, T., Saito, K., Nosaka, K., Shimomura, M., Mizuno, S., Nakamoto, Y. and Nakatsura, T. (2020) Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer. Cancer Sci. 111, 2736-2746.
DOI
|
27 |
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., Garg, K., Austin, J. H., Asamura, H., Rusch, V. W., Hirsch, F. R., Scagliotti, G., Mitsudomi, T., Huber, R. M., Ishikawa, Y., Jett, J., Sanchez-Cespedes, M., Sculier, J. P., Takahashi, T., Tsuboi, M., Vansteenkiste, J., Wistuba, I., Yang, P. C., Aberle, D., Brambilla, C., Flieder, D., Franklin, W., Gazdar, A., Gould, M., Hasleton, P., Henderson, D., Johnson, B., Johnson, D., Kerr, K., Kuriyama, K., Lee, J. S., Miller, V. A., Petersen, I., Roggli, V., Rosell, R., Saijo, N., Thunnissen, E., Tsao, M. and Yankelewitz, D. (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 6, 244-285.
DOI
|
28 |
Walton, G. M., Chen, W. S., Rosenfeld, M. G. and Gill, G. N. (1990) Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates. J. Biol. Chem. 265, 1750-1754.
DOI
|
29 |
Yu, H. A. and Riely, G. J. (2013) Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers. J. Natl. Compr. Canc. Netw. 11, 161-169.
DOI
|
30 |
Zhang, X., Gureasko, J., Shen, K., Cole, P. A. and Kuriyan, J. (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149.
DOI
|
31 |
Gazdar, A. F. (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28, S24-S31.
DOI
|
32 |
Goldberg, M. E., Montesion, M., Young, L., Suh, J., Greenbowe, J., Kennedy, M., Giaccone, G., Akerley, W. L., Dowlati, A., Creelan, B. C., Hicks, J. K., Hesketh, P. J., Kelly, K. L., Riess, J. W., Miller, V. A., Stephens, P. J., Frampton, G. M., Ali, S., Gregg, J. P. and Albacker, L. A. (2018) Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PLoS ONE 13, e0208097.
DOI
|
33 |
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T. and Mitsudomi, T. (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64, 8919-8923.
DOI
|
34 |
Harrison, P. T., Vyse, S. and Huang, P. H. (2020) Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin. Cancer Biol. 61, 167-179.
DOI
|
35 |
Jang, J., To, C., De Clercq, D. J. H., Park, E., Ponthier, C. M., Shin, B. H., Mushajiang, M., Nowak, R. P., Fischer, E. S., Eck, M. J., Janne, P. A. and Gray, N. S. (2020) Mutant-selective allosteric EGFR degraders are effective against a Broad Range of drug-resistant mutations. Angew. Chem. 59, 14481-14489.
DOI
|
36 |
Kishikawa, T., Kasai, T., Okada, M., Nakachi, I., Soda, S., Arai, R., Takigami, A. and Sata, M. (2020) Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: a retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Thorac. Cancer 11, 935-942.
DOI
|
37 |
Ciardiello, F. and Tortora, G. (2008) EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160-1174.
DOI
|
38 |
Morrow, M. R. and Grant, C. W. (2000) The EGF receptor transmembrane domain: peptide-peptide interactions in fluid bilayer membranes. Biophys. J. 79, 2024-2032.
DOI
|
39 |
Niederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V. and Engelman, J. A. (2015) The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 21, 3924-3933.
DOI
|
40 |
Batzer, A. G., Rotin, D., Urena, J. M., Skolnik, E. Y. and Schlessinger, J. (1994) Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol. Cell. Biol. 14, 5192-5201.
DOI
|
41 |
Finigan, J. H., Downey, G. P. and Kern, J. A. (2012) Human epidermal growth factor receptor signaling in acute lung injury. Am. J. Respir. Cell Mol. Biol. 47, 395-404.
DOI
|
42 |
Gao, X., Le, X. and Costa, D. B. (2016) The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Expert Rev. Anticancer Ther. 16, 383-390.
DOI
|
43 |
Grabe, T., Lategahn, J. and Rauh, D. (2018) C797S resistance: the undruggable EGFR mutation in non-small cell lung cancer? ACS Med. Chem. Lett. 9, 779-782.
DOI
|
44 |
Kenfield, S. A., Wei, E. K., Stampfer, M. J., Rosner, B. A. and Colditz, G. A. (2008) Comparison of aspects of smoking among the four histological types of lung cancer. Tob. Control 17, 198-204.
DOI
|
45 |
Ko, B., Paucar, D. and Halmos, B. (2017) EGFR T790M: revealing the secrets of a gatekeeper. Lung Cancer 8, 147-159.
DOI
|
46 |
Lee, S., Kim, J., Duggirala, K. B., Go, A., Shin, I., Cho, B. C., Choi, G., Chae, C. H. and Lee, K. (2018) Allosteric inhibitor TREA-0236 containing non-hydrolysable quinazoline-4-one for EGFR T790M/C797S mutants inhibition. Bull. Korean Chem. Soc. 39, 895-898.
DOI
|
47 |
Piotrowska, Z., Niederst, M. J., Karlovich, C. A., Wakelee, H. A., Neal, J. W., Mino-Kenudson, M., Fulton, L., Hata, A. N., Lockerman, E. L., Kalsy, A., Digumarthy, S., Muzikansky, A., Raponi, M., Garcia, A. R., Mulvey, H. E., Parks, M. K., DiCecca, R. H., Dias-Santagata, D., Iafrate, A. J., Shaw, A. T., Allen, A. R., Engelman, J. A. and Sequist, L. V. (2015) Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 5, 713-722.
DOI
|
48 |
Kobayashi, Y. and Mitsudomi, T. (2016) Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 107, 1179-1186.
DOI
|
49 |
Eck, M. J. and Yun, C. H. (2010) Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim. Biophys. Acta 1804, 559-566.
DOI
|
50 |
Karachaliou, N., Fernandez-Bruno, M., Bracht, J. W. and Rosell, R. (2018) EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients. Transl. Cancer Res. 8, S23-S47.
|
51 |
Lu, X., Yu, L., Zhang, Z., Ren, X., Smaill, J. B. and Ding, K. (2018) Targeting EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) resistance mutations in NSCLC: current developments in medicinal chemistry. Med. Res. Rev. 38, 1550-1581.
DOI
|
52 |
Pao, W. and Chmielecki, J. (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat. Rev. Cancer 10, 760-774.
DOI
|
53 |
Roskoski, R., Jr. (2014) The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol. Res. 79, 34-74.
DOI
|
54 |
Schalm, S. S., Dineen, T., Lim, S. M., Park, C. W., Hsieh, J., Woessner, R., Zhang, Z., Wilson, K., Eno, M., Wilson, D., Williams, B., Campbell, J., De Savi, C., Stevison, F., Utt, C., Guzi, T., Dorsch, M., Hoeflich, K. and Chul Cho, B. C. (2020) 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC. Ann. Oncol. 31, S839.
|
55 |
Sharma, S. V., Bell, D. W., Settleman, J. and Haber, D. A. (2007) Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169-181.
DOI
|
56 |
Tanner, K. G. and Kyte, J. (1999) Dimerization of the extracellular domain of the receptor for epidermal growth factor containing the membrane-spanning segment in response to treatment with epidermal growth factor. J. Biol. Chem. 274, 35985-35990.
DOI
|
57 |
Jia, Y., Yun, C. H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., Palakurthi, S., Jang, J., Lelais, G., DiDonato, M., Bursulaya, B., Michellys, P. Y., Epple, R., Marsilje, T. H., McNeill, M., Lu, W., Harris, J., Bender, S., Wong, K. K., Janne, P. A. and Eck, M. J. (2016) Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature 534, 129-132.
DOI
|
58 |
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R. and Johnson, D. H. (2006) Paclitaxel-carboplatin alone or with bevacizumab for Non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550.
DOI
|